Loading…
NovaBridge Biosciences is projected to rise to $1.92 by 2027, a +1% move from its current price of $1.90. NBP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.82 | $1.90 | $1.98 | +0.05% |
| Jul 14 | $1.79 | $1.90 | $2.02 | +0.09% |
| Jul 15 | $1.77 | $1.90 | $2.05 | +0.14% |
| Jul 16 | $1.75 | $1.90 | $2.07 | +0.19% |
| Jul 17 | $1.73 | $1.90 | $2.10 | +0.23% |
| Jul 18 | $1.71 | $1.91 | $2.12 | +0.28% |
| Jul 19 | $1.70 | $1.91 | $2.14 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.70 | $1.91 | $2.14 | +0.33% |
| Week 2 | $1.63 | $1.91 | $2.25 | +0.66% |
| Week 3 | $1.58 | $1.92 | $2.34 | +0.99% |
| Week 4 | $1.53 | $1.93 | $2.42 | +1.32% |
| Week 5 | $1.50 | $1.93 | $2.49 | +1.65% |
| Week 6 | $1.47 | $1.94 | $2.56 | +1.99% |
| Week 7 | $1.44 | $1.94 | $2.63 | +2.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NovaBridge Biosciences is a biotechnology company that engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology, and its product pipeline includes givastomig, a CLDN18.2 bispecific antibody, which is in phase 2 in combination with nivolumab and chemotherapy for gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; a Phase 1b program in first-line gastric cancer in combination with nivolumab and chemotherapy. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1 clinical trial for multiple solid tumors.
It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and a license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and changed its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NovaBridge Biosciences trades under the symbol NBP and is positioned in the Healthcare sector. The stock is currently priced at $1.93, with a market cap of $223.2M and a rank of 3747. The near-term outlook includes a neutral 2026 forecast with an average price of $1.93 and a 0 ROI, reflecting a stable starting point.
The long-run forecast shows meaningful upside from 2031 onward, with notable jumps in average price and ROI through 2040 and 2050. The forecast landscape highlights a path from modest near-term movement to substantial longer-term appreciation, driven by ongoing clinical programs and strategic collaborations.
A major floor 38.6% below — a decisive break under it would weaken the trend.
The nearest floor, 22.6% below — buyers have tended to step in here.
The nearest ceiling, 12.6% above — a clean break opens room to run.
A major ceiling 91.6% above — clearing it would confirm fresh momentum.
Key NBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.94 | Sell | $1.92 | Sell |
| MA 10 | $1.94 | Sell | $1.89 | Buy |
| MA 20 | $1.74 | Buy | $1.83 | Buy |
| MA 50 | $1.86 | Buy | $1.94 | Sell |
| MA 100 | $2.34 | Sell | $2.30 | Sell |
| MA 200 | $3.25 | Sell | $2.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.86 | Neutral |
| Stoch RSI (14) | 53.82 | Neutral |
| CCI (20) | 50.46 | Neutral |
| Williams %R (14) | -39.34 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 18.01 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 60.66 | Neutral |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | 0.21 | Buy |
| Ultimate (7,14,28) | 52.92 | Neutral |
| Momentum (10) | 0.30 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 1.89 | Buy |
| ADX (14) | 25.73 | Buy |
| ATR (14) | 0.07 | Info |
Technically, the near term shows bullish sentiment with an RSI of 60. The 50-day simple moving average sits at $1.88, while the 200-day simple moving average is at $3.27, suggesting that momentum may push prices higher if resistance around $2.14 holds. The current price of $1.93 sits above the 50-day SMA, underscoring a short-term positive bias.
The stock’s 30-day range spans from $1.44 to $2.59, with a nearby support at $1.47 and a resistance at $2.14.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.47 | $1.90 | $2.73 | 0% | Neutral | |
| $1.45 | $1.92 | $2.74 | +1% | Neutral | |
| $1.35 | $1.88 | $2.83 | -1% | Neutral | |
| $1.37 | $1.98 | $3.10 | +4% | Neutral | |
| $1.23 | $1.84 | $2.99 | -3% | Neutral | |
| $1.46 | $2.26 | $3.78 | +19% | Neutral | |
| $1.69 | $2.71 | $4.65 | +42% | Bullish | |
| $1.67 | $2.75 | $4.84 | +45% | Bullish | |
| $1.84 | $3.11 | $5.59 | +64% | Bullish | |
| $1.61 | $2.79 | $5.13 | +47% | Bullish | |
| $2.22 | $4.40 | $8.78 | +132% | Bullish | |
| $2.85 | $6.34 | $14.23 | +234% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.47 | $1.90 | $2.39 | +0.00% |
| August 2026 | $1.68 | $2.02 | $2.50 | +6.09% |
| September 2026 | $1.64 | $1.98 | $2.50 | -1.63% |
| October 2026 | $1.67 | $2.04 | $2.62 | +3.00% |
| November 2026 | $1.73 | $2.13 | $2.77 | +4.48% |
| December 2026 | $1.68 | $2.09 | $2.73 | -2.25% |
Click any year to see its month-by-month NBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NBP is projected to trade between $1.47 and $2.73, averaging $1.90 — a potential gain of 0% from today's $1.90. A consolidation phase looks the most probable path here.
NovaBridge Biosciences's 2027 outlook centres on $1.92, within a $1.45 to $2.74 range. That is up +1% on the projected 2026 average. That marks a +1% change versus current levels. Price action looks broadly range-bound.
By 2028, NBP could reach as high as $2.83, with a base case around $1.88 and support toward $1.35 — roughly -1% from $1.90. A consolidation phase looks the most probable path here.
Expect NBP to range from $1.37 to $3.10 through 2029. The $1.98 average target implies a +4% move from current prices. That is up +5% on the projected 2028 average. Price action looks broadly range-bound.
The NBP price prediction for 2030 points to an average of $1.84 (low $1.23, high $2.99) — a potential decline of -3% on today's $1.90. A consolidation phase looks the most probable path here.
In 2031, NBP is projected to trade between $1.46 and $3.78, averaging $2.26 — a potential gain of +19% from today's $1.90. That is up +23% on the projected 2030 average. Price action looks broadly range-bound.
NovaBridge Biosciences's 2032 outlook centres on $2.71, within a $1.69 to $4.65 range. That is up +20% on the projected 2031 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, NBP could reach as high as $4.84, with a base case around $2.75 and support toward $1.67 — roughly +45% from $1.90. Momentum favours further upside here.
Expect NBP to range from $1.84 to $5.59 through 2034. The $3.11 average target implies a +64% move from current prices. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The NBP price prediction for 2035 points to an average of $2.79 (low $1.61, high $5.13) — a potential gain of +47% on today's $1.90. Momentum favours further upside here.
In 2040, NBP is projected to trade between $2.22 and $8.78, averaging $4.40 — a potential gain of +132% from today's $1.90. That is up +58% on the projected 2035 average. Buyers look set to stay in control over this stretch.
NovaBridge Biosciences's 2050 outlook centres on $6.34, within a $2.85 to $14.23 range. That is up +44% on the projected 2040 average. That marks a +234% change versus current levels. Momentum favours further upside here.
Investing $1,000 in NBP today (≈ 526.315789 NBP) could be worth
$3,337.61
+$2,337.61 (+234%) by 2050 · US Dollar
Based on the average projected NBP price of $6.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NBPwould be worth at today's price.
$1,000 invested in NBP on Jul 10, 2025 (≈ 487.804889 NBP) would be worth
$926.83
-$73.17 (-7.3%) today · 0.93× · US Dollar
Based on a NBP entry price of $2.05 vs. today's $1.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.14 | $887.85 | -11.2% |
| 1 month ago | $1.53 | $1,241.83 | +24.2% |
| 3 months ago | $2.36 | $805.08 | -19.5% |
| 6 months ago | $3.72 | $510.75 | -48.9% |
| 1 year ago | $2.05 | $926.83 | -7.3% |
| All time (5.0y) ago | $76.33 | $24.89 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NBP forecast.
Our base-case forecast reaches $3.80 around 2040.
Implied market cap at $3.80: $439.46M
The multi-year forecast paints a picture of evolving upside potential. In 2026 the average price is $1.93 with a 0 ROI and neutral sentiment, indicating a flat near term. Through 2027–2030, the average price ranges from $1.96 to $1.90 with modest to negative ROI in some years, reflecting near-term volatility.
Starting in 2031, the outlook turns more bullish: avg $2.38 (ROI 23.1) and then rising to $2.85 (ROI 47.6) in 2032, $2.90 (ROI 50.5) in 2033, and $3.28 (ROI 69.8) in 2034, before easing to $2.91 (ROI 50.9) in 2035. The forecast accelerates meaningfully by 2040, with avg $4.72 (ROI 144.6), and then by 2050, avg $6.74 (ROI 249). These figures reflect significant upside if clinical progress and partnerships translate into sustained value.
It should be noted these are estimates, not guarantees, and actual results will depend on clinical outcomes, regulatory decisions, and market factors. The pipeline progress and licensing agreements with key partners contribute as potential drivers of upside, alongside ongoing collaborations with Bristol Myers Squibb and AbbVie.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $1.90 with a min of $1.25 and a max of $3.13, and a ROI of -1.3, with a neutral sentiment.
Short-term expectations for 2026 show an avg price of $1.93 with a 0 ROI and neutral sentiment. Long-term forecasts indicate bullish potential starting 2031, with substantial upside by 2040 and 2050, though these are estimates and not guarantees.
Yes. The 2035 forecast shows a max of $5.43 and an avg of $2.91, indicating that reaching or exceeding $4 is possible in the high-case scenario.
The stock shows bullish sentiment with an RSI of 60. The 50-day SMA is $1.88 and the 200-day SMA is $3.27. The 30-day range is $1.44 to $2.59, with support at $1.47 and resistance at $2.14.
Current price is $1.93 and the market cap is $223.2M.
NovaBridge Biosciences Community Discussion
0Share your NovaBridge Biosciences price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.